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Abstract
Background: Whereas there is increasing evidence that loss of expression and/or function of the thyroid hormone receptors
(TRs) could result in a selective advantage for tumor development, the relationship between thyroid hormone levels and
human cancer is a controversial issue. It has been reported that hypothyroidism might be a possible risk factor for liver and
breast cancer in humans, but a lower incidence of breast carcinoma has been also reported in hypothyroid patients
Methodology/Principal Findings: In this work we have analyzed the influence of hypothyroidism on tumor progression and
metastasis development using xenografts of parental and TRb1–expressing human hepatocarcinoma (SK-hep1) and breast
cancer cells (MDA-MB-468). In agreement with our previous observations tumor invasiveness and metastasis formation was
strongly repressed when TRb–expressing cells were injected into euthyroid nude mice. Whereas tumor growth was retarded
when cells were inoculated into hypothyroid hosts, tumors had a more mesenchymal phenotype, were more invasive and
metastatic growth was enhanced. Increased aggressiveness and tumor growth retardation was also observed with parental
cells that do not express TRs.
Conclusions/Significance: These results show that changes in the stromal cells secondary to host hypothyroidism can
modulate tumor progression and metastatic growth independently of the presence of TRs on the tumor cells. On the other
hand, the finding that hypothyroidism can affect differentially tumor growth and invasiveness can contribute to the
explanation of the confounding reports on the influence of thyroidal status in human cancer.
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Introduction
The thyroid hormone receptors, encoded by the TRa and TRb
genes, are ligand-dependent transcription factors that belong to
the nuclear receptors superfamily [1,2]. In addition to the well-
known role of these receptors in growth, development and
metabolism, there is increasing evidence that they have profound
effects on cell proliferation and malignant transformation.
Reduced expression of TRs as well as alterations in TR genes
are common events in many types of human cancer [3–14]. In
particular, aberrant TRs that act as dominant-negative inhibitors
of wild-type TR activity have been found in more than 70% of
human hepatocellular carcinomas [15–18], and biallelic inactiva-
tion of TRb by promoter methylation as well as mutations in this
gene are also frequent in breast cancers [19,20]. The tendency for
TRb expression to disappear as malignancies progress suggests
that TRb can act as a tumor suppressor in human cancers and
that therefore loss of expression and/or function of this receptor
could result in a selective advantage for cell transformation and
tumor development [21]. We have re-expressed TRb1i n
hepatocarcinoma and breast cancer cell lines that have lost
receptor expression and have analyzed the effect of the receptor in
tumor progression and metastatic growth. The results obtained
demonstrated that TRb1 expression retards tumor growth, causes
partial mesenchymal to epithelial cell transition and has a strong
suppressor effect on invasiveness, extravasation and metastasis
formation in nude mice [22]. In addition, studies with mice
expressing a dominant negative TRb mutant spontaneously
develop metastastic thyroid carcinoma [23] and pituitary tumors
[24], and increased aggressiveness of skin tumors is found in
genetically modified mice lacking TRs [22], further demonstrating
the role of these receptors as inhibitors of tumor progression.
In contrast with the role of TRs as tumor suppressors, no
consistent association between thyroidal status and cancer has
been demonstrated. For instance, the connection between thyroid
disorders and human breast cancer is a controversial issue.
Beatson proposed the use of thyroid extracts for breast cancer
treatment more than a century ago [25], and hypothyroidism has
been described to be frequently found in cancer patients and to be
associated with poor response to therapy [26–28]. However, a
lower incidence of primary breast carcinoma and reduced risk of
developing invasive disease have been also reported in hypothy-
roid patients [29]. Hypothyroidism appears to be clinically
favorable in patients with glioblastoma multiforme, since treat-
ment with the anti-thyroidal drug propylthiouracil in combination
with tamoxifen appears to increase survival [30]. On the other
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possible risk factor for liver cancer in humans [31], and thyroid
hormone administration also influences hepatocarcinoma progres-
sion in experimental animals. Thus, T3 treatment in rats, despite
causing liver hyperplasia, induces a rapid regression of carcinogen-
induced hepatic nodules and reduces the incidence of hepatocar-
cinoma and lung metastasis [32–34].
In this work we have examined the effect of hypothyroidism on
tumor growth, invasion and formation of metastasis by hepatocar-
cinoma and breast cancer cells in nude mice. In order to analyze if
the changes caused by hypothyroidism are dependent on a direct
effect of the hormone in the tumor cell through binding to TRs, we
have used both parental SK-hep1 and MDA-MB-468 cells that do
not express the receptors and cells in which TRb1 has been re-
expressed [22]. The results obtained demonstrated that hypothy-
roidism has a dual effect on tumorigenesis. Tumor growth is slower
in hypothyroid mice, but the tumors are more aggressive and
invasive, and metastasis formation is strongly enhanced. Since these
changes are observed in animals inoculated both with parental and
TR-expressing cells, they appear to be secondary to changes in the
stromal cells as a consequence of host hypothyroidism.
Results
Hypothyroidism retards tumor growth
Nude mice were made hypothyroid by treatment with anti-
thyroidal drugs 4 weeks before inoculation of tumor cells (Figure 1).
This treatment significantly retarded the growth of the animals
that at the end of the experiments showed a decreased weight in
comparison with the untreated controls, strongly reduced the
levels of circulating thyroxine, and also markedly decreased
transcript levels for deiodinase 1 in liver, a sensitive marker for
tissue hypothyroidism [35]. SK and SK-TRb cells were inoculated
subcutaneously into the flanks of control and hypothyroid nude
mice and tumor growth was followed (Figure 2). In agreement with
our previous observations [22], in euthyroid animals expression of
TRb retarded the detection of palpable tumors (Figure 2A) and
significantly reduced tumor volume during the first weeks
(Figure 2B). Furthermore, hypothyroidism retarded tumor growth
in mice inoculated with both SK and SK-TRb cells, although the
reduction was more marked in the case of the TRb-expressing
cells. When MDA cells were inoculated orthotopically in the
mammary gland, tumor appearance was slightly retarded in
hypothyroid animals in both parental and TRb-expressing cells
(Figure 2C) and tumor volume was also smaller (Figure 2D),
although differences were less marked than those observed with
hepatocarcinoma cells and were only statistically significant at 9
weeks post-inoculation of MDA-TRb cells.
The reduced tumor volume in hypothyroid hosts correlated
with a lower proliferation in tumor biopsies obtained at the end of
the experimental period (Figure 3A). Ki67 labeling showed that
tumors originated in control mice from parental SK and MDA
cells were highly proliferative and that hypothyroidism reduced
the number of cells expressing this proliferation marker. In
addition, TRb-expressing cells gave rise to tumors with a lower
proliferation index and this reduction was stronger in MDA-TRb
tumors in the hypothyroid mice. Decreased proliferation was
accompanied by enlargement of the necrotic area of the tumors
grown in hypothyroid mice and, as shown in Figure 3B, this
increase occurred both in parental and TRb-expressing cells.
Expression of Cyclin E, other proliferation marker, was reduced
in biopsies of both hepatocarcinoma (Figure 4A) and breast cancer
tumors (Figure 4B) developed in hypothyroid hosts, and also in this
case the effect was observed independently of the presence of
TRb. In addition, reduced proliferation, assessed by BrdU
incorporation, was observed in explants obtained from SK and
SK-TRb tumors when xenografts were grown in hypothyroid
hosts (Figure 4C).
Figure 1. Induction of hypothyroidism. (A)-Weight of control mice and mice treated orally with anti-thyroidal drugs. Mice were treated for 1
month before inoculation of tumor cells. (B)-Circulating levels of T4 measured at the end of the treatment. (C)-mRNA levels of deiodinase 1 (Dio1) in
livers from control and hypothyroid mice.
doi:10.1371/journal.pone.0006428.g001
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TRb expression was analyzed by immunohistochemistry in SK
and SK-TRb tumors excised at 30 days post-inoculation. As
expected, TRb was not detected in the parental hepatocarcinoma
cells, although it could be detected in infiltrating inflammatory
cells from the host. On the other hand, the receptor was present
in most cells of the tumors formed by SK-TRb cells in euthyroid
mice and receptor expression appeared to be stronger when
tumors were developed in hypothyroid mice (Figure 5A). A
similar increase was obtained when TRb mRNA levels were
quantified (Figure 5B). Furthermore, in explants obtained 13 and
25 days after cell implantation a reduction of TRb expression
with respect to the levels present in the inoculated cells was
detected by Western blot and by immunofluorescence
(Figure 5C). In the explants an increase in TRb mRNA levels
was also observed when the cells were derived from tumors
developed in hypothyroid hosts (Figure 5C). Reduction of
receptor expression during tumor growth was observed later
with MDA-TRb cells. In sections of MDA-TRb cell xenografts,
immunohistochemistry of TRb demonstrated expression of the
receptorat 30dayspost-inoculation and thisexpression was again
stronger in tumors grown in hypothyroid mice (Figure 5D). TRb
expression was confirmed by western blot in tumor explants
obtained at this time point (Figure 5E). In contrast, in MDA-TRb
tumors examined at 45 days post-inoculation few positive tumor
cells were found (Figure 5D). These results suggest that loss of
TRb expression appear to confer a selective advantage to the
hepatocarcinoma and breast cancer cells for tumor growth and
that receptor loss is retarded when tumors are developed in
hypothyroid hosts.
Hypothyroidism enhances the mesenchymal phenotype
of the tumors
We have previously observed that TRb1 causes a partial
mesenchymal to epithelial transition in the hepatocarcinoma and
breast cancer tumors, decreasing the levels of the mesenchymal
marker vimentin and increasing the epithelial marker cytokeratin
8/18. Other epithelial marker, b-catenin, was absent in xenografts
from MDA cells, but it was expressed in xenografts from TRb1-
expressing SK cells [22]. As shown in Figure 6A, when cells were
inoculated in hypothyroid mice, tumors from both parental and
TRb1-expressing SK and MDA cells had a more mesenchymal
phenotype with a strong reduction of keratin 8/18 and b-catenin
and a concomitant increase in vimentin. Quantification of the
percentage of cells positive for these markers confirmed a strong
reduction in the expression of the epithelial marker and a
significant increase in the expression of the mesenchymal marker
in tumors grown in hypothyroid hosts (Figure 6B). In addition, a
strong reduction in cytokeratin 8/18 levels was observed by
immunofluorescence in explants derived from hepatocarcinoma
SK and SK-TRb tumors originated in the hypothyroid mice
(Figure 6C). These results show that hypothyroidism confers a less
differentiated phenotype to the tumors independently of the
presence of the receptor in the cancer cells.
Hypothyroidism increases tumor invasiveness
Tumors originated from SK cells in normal nude mice are
highly infiltrative, presenting an elevated number of invasion
fronts. In contrast, tumors from SK-TRb cells were less infiltrative,
presenting a clearly detectable pseudocapsule of collagen and
inflammatory cells, and a reduced number of invasion fronts
Figure 2. Hypothyroidism retards tumor growth. (A)-Tumor incidence in euthyroid and hypothyroid nude mice injected heterotopically into
both flanks with parental (SK) and TRb1-expressing (SK-TRb) hepatocarcinoma cells. (B)-Tumor volume was measured at different time points after
inoculation in the same experimental groups. (C)-MDA and MDA-TRb cells were inoculated orthotopically into the mammary fat pad of both groups
of mice and tumor appearance was followed. (D)-Tumor volume in xenografts of parental and TRb-expressing MDA cells. Data are mean6S.E.
doi:10.1371/journal.pone.0006428.g002
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were inoculated into hypothyroid mice, since tumors acquired a
more invasive phenotype with a significant increase in the number
of invasion fronts. In addition, all hypothyroid animals injected
with SK cells had tumors that infiltrated adjacent muscle, lymph
and blood vessels or skin (Figure 7B), whereas some of the tumors
from euthyroid animals did not invade these tissues. Furthermore,
no tumors developed in normal mice caused the appearance of
lung or liver metastasis, but such long distance metastasis in these
tissues were present in 25% of the hypothyroid animals. In
accordance with the less infiltrative pattern of SK-TRb1 tumors,
distant metastasis were not detected in either control or
hypothyroid mice and invasion of surrounding tissues was strongly
reduced, although it increased in hypothyroid mice (Figure 7B).
Hypothyroidism of the host mice also increased invasiveness of
MDA cells. Tumors formed by parental MDA cells in euthyroid
mice present a diffuse highly invasive growth pattern, whereas
MDA-TRb cells give rise to tumors with a more compact
structure. As in the case of SK-TRb tumors, they are surrounded
by a pseudocapsule and present a reduced number of invasion
fronts (Figure 7C). This pattern is lost in MDA-TRb tumors
developed in hypothyroid hosts, where the tumors were more
aggressive and the number of invasion fronts increased strongly
(Figure 7C). In addition, 30% of the tumors from MDA-TRb cells
are delimited by a macroscopic gelatinous capsule (that is not
found in tumors from cells lacking the receptor) and this
percentage was reduced to 10% in the hypothyroid mice
(Figure 7D). Muscle and vessels infiltration of MDA and MDA-
TRb tumors also increased in the hypothyroid mice, and long
distant metastasis in bone were detected in MDA tumors
developed in hypothyroid but not in euthyroid animals (Figure 7D).
As an additional approach to evaluate changes in tumor
infiltration, we also examined connective tissue organization by
the Picrosirius red (PSR) staining technique. Under polarized light,
the color of PSR staining varies depending on collagen fiber
thickness and packing density [36]. Characteristically, red color
indicates tightly packed collagen fibers whereas sites of tumor
invasion exhibit green birefringence typical of increased extracel-
lular matrix degradation. As shown in Figure 8, red staining
characteristic of a well developed collagen pseudocapsule was only
clearly detected in tumors formed by TRb-expressing cells in
control mice, whereas green color was predominant in tumors
originating from parental cells. Quantification of the area stained
in red, demonstrated that the increase observed in the TRb-
expressing tumors was notably reversed when they were developed
in hypothyroid hosts, in agreement with the increased invasion
found under these conditions.
Formation of experimental metastasis is enhanced in
hypothyroid mice
The influence of hypothyroidism on formation of experimental
metastasis was examined by comparing the appearance of lung
metastasis upon inoculation of parental and TRb-expressing cells
into the tail vein of normal nude mice and mice treated previously
with anti-thyroidal drugs. In agreement with our previous
observations [22], most normal animals injected with parental
SK cells developed nodular metastasis in the lungs, whereas less
than 20% of the animals injected with SK-TRb cells developed
metastasis (Figure 9A and B). Hypothyroidism significantly
increased the incidence of lung metastasis and under these
conditions up to 70% of mice inoculated with TRb-expressing
cells had metastatic lesions. The number of metastasis per lung was
also strongly enhanced in hypothyroid mice injected with either
parental or SK-TRb cells and the same occurred with the area of
the tissue affected (Figure 9B).
Strong enhancement by hypothyroidism of metastasis formation
by MDA and MDA-TRb cells was also observed. When
inoculated into euthyroid animals MDA-TRb cells had a markedly
reduced metastatic capacity with respect to the cells that lack the
receptor (Figure 9C), and this capacity increased significantly
when the cells were inoculated in hypothyroid mice. As in the case
of hepatocarcinoma cells, not only incidence of metastasis, but also
the number of metastatic lesions and the area of the lung
parenchyma affected, was significantly enhanced when either
parental or MDA-TRb cells were injected into the mice treated
with the anti-thyroidal drugs (Figure 9D).
Discussion
There is increasing evidence that reciprocal interactions
between the tumor cells and the stromal cells of the tumor
microenvironment of the host are critical for tumor progression
Figure 3. Hypothyroidism reduces tumor proliferation and
increases necrosis. (A)-The percentage of cells expressing the
proliferation marker Ki67 was determined by immunohistochemistry
in biopsies of the tumors formed by parental and TRb-expressing SK
and MDA cells in control and hypothyroid nude mice. (B)-Hypothyroid-
ism increased the necrotic area of the tumors determined from H&
staining. Data are mean6S.E.
doi:10.1371/journal.pone.0006428.g003
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PLoS ONE | www.plosone.org 4 July 2009 | Volume 4 | Issue 7 | e6428Figure 4. Hypothyroidism reduces Cyclin E expression and BrdU incorporation. (A)-Immunohistochemical staining for Cyclin E in biopsies
from SK, SK-TRb, MDA and MDA-TRb tumors developed in control and hypothyroid nude mice. (B)-Quantification of the percentage of cells
expressing Cyclin E in tumors of the different groups. (C)-BrdU incorporation was measured in explants from SK and SK-TRb tumors resected after 25
days of inoculation in control and hypothyroid mice.
doi:10.1371/journal.pone.0006428.g004
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experimental hypothyroidism in mice has a profound effect on
invasiveness and formation of metastasis by hepatocarcinoma and
breast cancer cells independently of the cellular expression of TRs.
Epithelial-mesenchymal transition plays a key role in tumor
invasion by disrupting intercellular contacts and enhancing
motility and migration of tumor cells to the surrounding tissues
[39,40]. We have observed that tumors developed from cells
inoculated into hypothyroid nude mice had a more undifferenti-
ated phenotype than those injected into euthyroid mice, as
evidenced by enhanced expression of epithelial markers such as
keratin 8/18 or b-catenin and by reduced expression of
mesenchymal markers such as vimentin. This mesenchymal
phenotype can facilitate spreading from the primary tumor to
the neighboring host tissues, a critical step that allows tumor cells
to invade the extracellular matrix, enter the circulation and
disseminate to distant organs.
We have also found that tumors formed in hypothyroid hosts
showed changes in the extracellular matrix as demonstrated by a
change in the polarization colors of PSR staining from red to
green. It is assumed that unpacking of the collagen fibers may
facilitate invasion of the surrounding tissues by the tumors, and
predominance of green color indicates that the collagen molecules
are loosely packed and could be composed of procollagens,
Figure 5. Hypothyroidism prevents TRb loss during tumor growth. (A)-Immunohistochemical staining for TRb expression after 30 days of
inoculation of SK and SK-TRb cells in the flanks of control and hypothyroid mice. In the tumors some host inflammatory cells, labeled with arrows,
appear to be positive for TRb. (B)- TRb mRNA levels analyzed by real time PCR in these tumors. (C)-Detection of TRb by western blot in explants from
individual tumors of SK and SK-TRb cells obtained 13 and 25 days post-inoculation. Lanes 1 and 2 show TRb levels of the injected SK and SK-TRb cells.
The lower panels show the immunofluorescence staining for TRb in the explants. Nuclei were stained with DAPI. (D)-TRb mRNA levels in explants
from SK and SK-TRb tumors excised 25 days after inoculation of cells in control and hypothyroid mice. (E)-TRb expression detected by
immunohistochemistry in tumors excised after 30 and 45 days of orthotopical inoculation of MDA and MDA-TRb cells into control and hypothyroid
hosts. Inflammatory cells are marked with arrows (F)-Levels of TRb detected by western blot in the injected cells (day 0) and in explants obtained from
MDA and MDA-TRb tumors at 30 days post-inoculation.
doi:10.1371/journal.pone.0006428.g005
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PLoS ONE | www.plosone.org 6 July 2009 | Volume 4 | Issue 7 | e6428Figure 6. Hypothyroidism enhances the mesenchymal phenotype of tumors. (A)-Immunohistochemical staining for vimentin, cytokeratin 8/
18 and b-catenin showed that tumors from inoculated parental SK and MDA cells, as well as from cells expressing TRb1, showed an increase of the
mesenchymal marker and a reduction of epithelial markers. (B)-Quantification of the percentage of cells from the different tumors expressing
cytokeratin 8/18 and vimentin. (C)- Cytokeratin 8/18 expression analyzed by immunofluorescence in explants obtained from tumors excised after 25
days of inoculation of SK and SK-TRb cells into control and hypothyroid mice.
doi:10.1371/journal.pone.0006428.g006
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normal fibers [41,42]. In accordance with the alteration in the
extracellular matrix, as well as with the changes in the tumor cell
phenotype, hypothyroidim increased the number of invasion
fronts of the tumors and strongly augmented infiltration of
adjacent tissues such as muscle, blood and lymph vessels or skin.
Thyroidal status also influenced the formation of long distance
metastasis by hepatocarcinoma and breast cancer cells. Thus,
spontaneous metastasis in tissues such as lung, liver or bone
appeared when cells were injected into hypothyroid but not
euthyroid hosts, reinforcing the concept that metastatic growth is
dependent on both the intrinsic properties of the tumor cells and
the responses of the stromal cells. Furthermore, formation of
experimental metastasis in lung by direct inoculation of the cancer
cells into the tail vein of the hypothyroid nude mice was also
markedly enhanced with respect to the metastatic growth observed
in normal hosts. The process of metastasis requires a chain of
events (invasion, intravasation, survival in circulation, scattering to
distant tissues, extravasation into parenchyma, and colonization of
vital organs) that are rate limiting since a failure at any of them can
Figure 7. Hypothyroidism enhances tumor invasiveness. (A and C)-Representative H&E staining of tumors formed by parental and TRb-
expressing SK and MDA cells inoculated in control and hypothyroid nude mice (left panels). Tumors originated in hypothyroid hosts were more
invasive as illustrated by asterisks that denote sites of tumor invasion. The number of invasion fronts of the tumors was scored and is represented as
mean6S.E in the right panels. (B and D)-Quantification of the percentage of animals with tumors infiltrating surrounding tissues such as muscle,
blood and lymph vessels and skin or having long distance metastasis in lung, liver or bone. In the case of MDA cells, the number of tumor enveloped
by a conspicuous gelatinous capsule was also scored.
doi:10.1371/journal.pone.0006428.g007
Figure 8. Hypothyroidism causes unpacking of collagen fibers. (A)-Representative images of Picrosirius Red staining (PSR) of collagen in
tumors formed by parental and TRb-expressing SK and MDA cells. Tumors grown in control and hypothyroid mice were examined under polarized
light. Red staining characteristic of a well-developed tumor pseudocapsule with ordered collagen was only observed in tumors originating from TRb-
expressing cells inoculated in control hosts. (B)-Quantification of the red-stained areas in the different tumors. Data were calculated as cm
2 of red
staining/cm of tumor surface.
doi:10.1371/journal.pone.0006428.g008
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appears to sustain these different steps and to favor a permissive
tissue microenvironment for cancer metastasis.
The observed effects of hypothyroidism on invasion and
metastasis could be secondary to the actions of the thyroid
hormone on the tumor cell, the host stroma or both. The lower
hormone availability in animals treated with anti-thyroidal drugs
would decrease hormone binding to the receptors in the tumor cell
and host tissues and reduce its biological effects. We have shown
that in cultured hepatocarcinoma and breast cancer cells TRb
abolishes anchorage independent growth and migration, and that
when inoculated in mice causes partial mesenchymal to epithelial
transition and inhibits invasion and metastatic growth [22].
Therefore, a higher aggressiveness of the tumors developed from
TRb-expressing cells in hypothyroid hosts would be compatible
with a direct effect on the cancer cells as a consequence of reduced
TR activity. Other possibility was that TRb could be lost
selectively when the tumor cells proliferate in hypothyroid mice.
That this was not the case was demonstrated by the finding that,
although receptor levels were reduced during tumor formation,
this loss was even less marked under these conditions. Importantly,
we also observed increased malignancy of tumors formed by the
parental hepatocarcinoma and breast cancer cells that do not
respond to thyroid hormones because they do not express TRs
[22]. Therefore, the changes in the stromal cells associated with
low thyroid hormone levels rather than a direct effect on the
cancer cells appear to be responsible for the increased invasiveness
and metastatic activity observed in hypothyroid mice.
A bigger size of the tumors in hypothyroid mice would be
compatible with increased cancer cell dissemination and metastatic
colonization [45]. However, increased aggressiveness of tumors
developed in hypothyroid mice did not correlate with an increase in
tumor growth, rather tumors developed faster in euthyroid than in
hypothyroid hosts. These results agree with previous results from
our laboratory. We have demonstrated that TRs inhibit tumor
formation by the ras-oncogene in nude mice and that tumor
development by ras-transformed fibroblasts is retarded in hypothy-
roid animals [46]. Retardation of tumor growth in hypothyroid
miceoccurredwhenbothTRb–expressingcellsandcellsthatdonot
express the receptor were inoculated, suggesting again that changes
in the host stroma associated with hypothyroidism rather than a
direct receptor-mediated action on the tumor cells are responsible
for inhibition of tumor growth. However, the possibility that ‘‘non
genomic’’ actions of thyroid hormones mediated by putative
receptors different from TRs [47,48] could participate in the effect
of hypothyroidism on tumor growth, invasiveness and metastasis
development cannot be dismissed at present.
In summary, our data point to an important role of the
thyroidal status in tumor progression. Normal thyroid hormone
levels appear to favor growth of primary xenografts, but they also
block tumor cell dissemination and metastasis formation. These
divergent effects could help to explain the confounding reports on
the influence of hypothyroidism in human tumors. Furthermore,
since our results show that similar effects are observed indepen-
dently of the presence or absence of TR in the cancer cells, it
would be expected that thyroidal status could impact tumor
progression even in tumors in which TRs are deleted or mutated, a
common event in human cancer.
Materials and Methods
Ethics Statement
All animal work was done in compliance with the European
Community Law (86/609/EEC) and the Spanish law (R.D. 1201/
2005(), with approval of the Ethics Committee of the Consejo
Superior de Investigaciones Cientı ´ficas.
Cell lines
Parental SK-hep1 (SK) and MDA-MB-468 (MDA) cells, and
cells expressing TRb1 (SK-TRb and MDA-TRb, respectively),
were obtained and grown as previously described [22].
Xenografts
Groups of athymic nude mice (athymic nude-Nu) 8-10 weeks
old were used for xenografting studies. SK and SK-TRb cells
(1610
6 cells in 100 ml PBS) were injected subcutaneously into each
Figure 9. Hypothyroidism enhances formation of experimental lung metastasis. Control and hypothyroid mice were injected with parental
and TRb1-expressing cells into the tail vein and 30 days later lungs were excised mounted and stained. (A and C)-Representative images of lungs from
mice injected with MDA, MDA-TRb, SK and SK-TRb cells. Metastasis are delineated with a discontinuous blue line. (B and D)-The percentage of animals
bearing metastatic lesions, the number of lesions/lung, and the area of lung parenchyma affected (mean6S.E) were determined in the different groups.
doi:10.1371/journal.pone.0006428.g009
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and MDA-TRb cells were inoculated into the fat mammary pad
(10 animals/group) as previously described [22]. Similar injections
were performed in parallel in normal mice and in mice made
hypothyroid by treatment with 0.02% methymazole and 0.1%
sodium perchlorate in the drinking water [46]. Treatment started
4 weeks before inoculation and was continued for the duration of
the experiments. Tumor volume was measured every week and
only tumors with diameter .0,3 cm were considered. The weight
of the animals was recorded once a week and at sacrifice tumors
were excised, blood was taken for serum measurement of
thyroxine (T4) by means of specific radioimmunoassay [49] and
samples from different tissues were taken.
Histology and Immunohistochemistry
Tumors and tissues were processed for histopathologic proce-
dures by fixing in 4% buffered formalin and embedded in paraffin
wax. Sections were stained with H&E processed for immunohisto-
chemistry that was performed using standard protocols on
deparaffinized sections as previously described [22]. The antibodies
used were: TRb (sc-737; Santa Cruz Biotechnology), cytokeratin 8/
18 (NCL-5D3; Novocastra laboratories), vimentin (61013; Progen),
b-catenin (610154; Biodiagnostic), Cyclin E (7959 ABCAM), Ki67
(M7240; DakoCytomation). Ki67 was used to determine prolifer-
ation index (Ki67-positive cells/total cells) from 5 photographs
taken from 4–6 sections of each group (x400). The percentage of
cells expressing cyclin E, vimentin or cytokeratin 8/18 was also
scored in a similar way. Picrosiruis red (PSR) staining of collagen
was performed as described by Junqueira et al. [36]. Stained slides
were observed under polarized light using a Leica DMBL light
microscope microscope equipped with a polarizer/analyzer set.
Quantification of the red staining was performed using analysis@-
Soft Imaging System. To determine necrotic areas (necrotic cells/
total cells), tumors were scanned (Kodak Professional RES 3370)
and used for histometric counting. Necrotic cells were expressed
relative to total cells. Tumor perimeters were measured from
panoramic scannings of Trichromic stained tumors and the number
of invasion fronts per cm was scored visually.
Formation of experimental metastasis
For formation of experimental metastasis in lung, 1610
6 cells
were injected into the lateral tail vein of control nude mice and of
mice treated with the anti-thyroidal drugs for 30 days. Animals
were sacrified 30 days after inoculation, and lungs were excised
and stained with Masson Trichromic. The number of nodular
metastasis was visually scored from scans of the stained tissue, and
the total lung areas (x100) and lung areas affected by metastasis
(x1000) were calculated using anlySIS H Soft Imaging System.
Tumor explants
Tumor explants (2 mm) were prepared from tumors under
sterile conditions at different times. Explants were maintained in
DMEM:HAMS (1:1) with 10% FBS depleted of thyroid
hormones.
Western blot and antibodies
Proteins from cell lysates (20 mg) were separated in SDS-PAGE,
transferred to PDVF membranes (Immobilon, Millipore) and used
for Western analysis with the anti-TRb antibody (dilution 1:500).
Lamin, detected with antibody sc-6216 (Santa Cruz Biotechnol-
ogy, dilution 1:2000), was used as a loading control.
Immunofluorescence
Cells from tumor explants were grown on glass coverslips and fixed
in a solution containing 4% paraformaldehyde in PBS. Cells were then
permeabilized with 0,1% Triton X-100 and after saturation with PBS-
0,1 M Glycin were incubated for 2 h with the anti-TRb antibody
(1:200 dilution) or cytokeratin 8/18 antibody (1:100). Coverslips were
incubated with a fluorescein-tagged secondary antibody (Dakopatts) at
1:500 dilution and then mounted in Mowiol 4-88 (Hoechst AG).
Specimens were observed with an inverted photomicroscope (model
DMIRB HC; Leica). Fluorescence images were captured using a
cooled digital CCD Hamamatsu ORCA camera and digitally
recorded with the ImageProPlus 4.0 imaging software.
Bromo-deoxi-uridine (BrdU) incorporation
Cells derived from explants, grown on glass coverslips, were
incubated 1 h with BrdU. The assays were performed as
recommended by the manufacturer (Boheringer Mannheim
Biochemica) and cells were stained with DAPI.
Quantitative real-time PCR assays
Total RNA was extracted using Tri Reagent (Sigma) from the
livers of control and hypothyroid nude mice and deiodinase 1
mRNA levels were analyzed by quantitative RT-Q-PCR. RT was
performed with 2 mg of RNA following specifications of Super-
Script
TM First-Strand Synthesis System (Invitrogen Life Technol-
ogies). The primers for deiodinase 1 used were: 59-CTTCGGT-
GACAGTTTTGATGAGC-39 (forward) and 59-GCAACAGAT-
TTGGTGCTGGATG-3. TRb transcripts were determined in
RNA extracted from tumors and explants using the primers: 59-
CCACCT TCTTCAGCATCC-39 (forward) and 59-AGTCATC-
TACGAGTCTCTTG-39(reverse). PCRs reactions were per-
formed using a MX3005P instrument (Stratagene) and detected
with Sybr Green. Data analysis was done using the comparative
CT method and data were corrected with the GAPDH mRNA
levels.
Statistical analysis
The Kaplan–Meier method was used to estimate the percentage
of tumor free animals, and the Breslow test was used to test for
differences between curves using SPSS 12,0. ANOVA analysis was
used to evaluate statistical significance in tumor volume curves,
number of invasion fronts and necrotic area. Results are expressed
as the mean6SE of the indicated number of experiments. The
95% confidence intervals were calculated based on SE of the
mean. Statistical significance was estimated with Student’s t-test
for unpaired observations. In all cases: * p,0.05, **,p0.01, ***
p,0.001.
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